Association among CYP1 A2 genetic polymorphisms and the risk to develop acute lymphoblastic leukemia and serum concentrations of methotrexate

Shu-mei WANG,Lu-lu SUN,Wei-xin ZENG,Guo-liang ZHANG

DOI: https://doi.org/10.13699/j.cnki.1001-6821.2014.08.003

2014-01-01

Abstract:Objective To investigate the association among CYP 1A2*1F (C-163A) polymorphisms and the risk to develop acute lymphoblas-tic leukemia ( ALL) and serum concentrations of methotrexate.Methods Peripheral blood samples were obtained from healthy subjects ( n=283 ) as control samples and children with ALL ( n =91 ) to extract genome DNA.Polymerase chain reaction -Restriction fragment length polymor-phism (PCR-RFLP) was used to detect the genotypes of CYP 1A2*1F polymorphisms.Fluorescence polarization immunoassay ( FPIA) was em-ployed to determine the serum concentrations of MTX at the 24 h and 42 h.Results The frequencies of genotypes and alleles at CYP 1A2*1F in healthy subjects and ALL children met Hardy -Weinberg equilibrium.The frequency of A allele in ALL children ( 43.41%) was significantly lower than that in healthy subjects (64.66%) (P<0.01).The odds ra-tio ( OR) of A allele was 0.42 , significantly reducing the risk to develop ALL ( P<0.0001 ).There were no significant differences in the dose -adjusted serum concentration (C/D ratio) of MTX at the 24, 42 h among CC, CA and AA genotype groups.Conclusion CYP1A2*1F signifi-cantly reduces the risk to develop ALL and A allele is a protective allele for ALL.However , there is no significant association between CYP 1 A2*1 F polymorphism and serum concentrations of MTX in ALL children.